Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Controlled Trial.
Clin Oncol (R Coll Radiol)Jun 27, 2026 (epub)
V Murthy, P Maitre, S Priya et al.
✦ AI-curated · Sources linked
In 30 seconds
The RELAX trial is a multicenter, phase II randomized controlled trial evaluating a short regimen of androgen deprivation therapy (ADT) and androgen receptor-targeted agent (ARTA) combined with external beam radiotherapy (XRT) in high-risk prostate cancer. It compares 9 months of ADT and 6 months of ARTA to the standard 24-month ADT, with a primary endpoint of 5-year disease-free survival (DFS).
Key findings
- The trial aims for a non-inferiority margin of 10% from an expected 5-year DFS of 85% in the standard arm.
- Participants are monitored with serial serum PSA and testosterone levels, among other assessments.
- The planned accrual is 206 participants, with nearly a third of enrolment completed to date.
Why it matters
This study addresses the potential for a shorter treatment duration in high-risk prostate cancer, which may improve patient quality of life and reduce treatment burden while maintaining efficacy.